Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)

What is the purpose of this trial?

The purpose of the study is to collect information on patients who have been diagnosed with transthyretin-associated amyloidosis who carry a mutation in the gene that could lead to this disease.

Participation Guidelines

Ages: 18 years and older

Gender: Both

Pfizer Inc., U.S. Pharmaceuticals Group

Start Date: 06/04/2014

End Date: 06/30/2021

Last Updated: 06/22/2018

Study HIC#: 1306012239

Get Involved

For more information about this study, contact:
Lynn Wilson
+1 203-737-8871

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email or call 1-877-978-8348.

Trial Image


Daniel Jacoby

Principal Investigator